RxDoctor Payments Data

Tareck Nossuli, MD

Advanced Heart Failure and Transplant Cardiology · Lancaster, PANPI 1255492963

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,650 of the $3,987 with a category attached, or 66.5%. Novartis accounts for 78.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $2,979 and has fallen 94.4% since, to $166 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in PA, where the typical reported total is $4,440.

$3,987in general payments, 2019–2025

Across 46 payments — averaging $86.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Alnylam Pharmaceuticals Inc.$400
  • United Therapeutics Corporation$142
  • Abbott$139
  • E.r. Squibb & Sons, L.L.C.$75
  • Actelion Pharmaceuticals US, Inc.$35
  • plus $64 from 3 others
$321,491in research payments, 2019–2025

Across 64 payments — averaging $5023.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$273K
  • Amgen$37K
  • Ionis Pharmaceuticals, Inc.$11K

What the payments were for

  • Speaking & faculty fees$2,65066%
  • Food & beverage$1,33734%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,987 in reported general payments places this provider in the 45th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$171,058
Medicare patients
1,256
Services billed
2,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis171$3,725,710
EntrestoSacubitril/Valsartan246$286,781
JardianceEmpagliflozin144$144,629
FarxigaDapagliflozin Propanediol165$137,038
EliquisApixaban74$93,455
CamzyosMavacamten12$82,019
XareltoRivaroxaban16$21,587
Torsemide94$4,073
Ranolazine ErRanolazine36$3,802
Metoprolol Succinate219$3,266
Spironolactone357$2,343
Rosuvastatin Calcium94$1,974
Potassium Chloride22$1,652
Furosemide267$1,599
Atorvastatin Calcium123$1,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$14$3,819,165245 claims
NovartisEntresto$3,132$286,781246 claims
AstraZenecaFarxiga$16$137,038165 claims
E.r. Squibb & Sons, L.L.C.Camzyos$75$82,01912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →